GLP-3 R + Cagrilintide
Also known as: GLP-3 R + Cagri, Triple Agonist + Amylin Stack
An experimental pairing that adds an amylin-based satiety signal on top of a single-molecule GLP-1/GIP/glucagon triple agonist.
Components
How it's combined
Research framing extends the amylin-add-on logic of CagriSema to a triple agonist: GLP-3 R acts on GLP-1, GIP, and glucagon receptors, while cagrilintide (a long-acting amylin analog) adds a hindbrain fullness pathway none of those receptors cover. The evidence for this specific pairing is thin: a single rodent study (obese male rats) reported greater weight loss with the combination than with either agent alone, and there is no published human trial. Both components are investigational, and stacking two potent appetite suppressors compounds GI side effects such as nausea and vomiting. Once-weekly subcutaneous dosing is typical of each component in trials.
Available from vendors
PeptideChat is an independent research resource, not the seller. Links go to third-party vendors; products are sold strictly as research chemicals and are not intended for human consumption. We may earn a commission on purchases. Disclosure
Independent research resource
Not a seller — PeptideChat doesn't sell or ship products.
Research-use-only framing
Content is educational, not a dosing recommendation.
Vendor links clearly disclosed
Outbound links to third-party vendors are always labeled.